Research & Development World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE

Hype, Hope, Reality

By R&D Editors | April 12, 2012

A recent NOVA program on PBS, Cracking Your Genetic Code, examined the rapidly moving developments in genetics research and the impact on the public and patients. The program, produced with The Hastings Center, a non-partisan bioethics research center, asked the question: “What will it mean when most of us can afford to have the information in our DNA—all six billion chemical letters of it—read, stored, and available for analysis?”

One clear message from the program was that science and technology have revealed an overwhelming mass of information since the completion of the first human DNA sequence nine years ago. While researchers have more data, and there has been some progress in understanding disease and developing treatments, we still have long way to go. Now that we know more about the human genome, in some ways, we actually know less. As researchers continue to explore the information, some commercial ventures are offering genetic analysis as an online purchase.

Among the many messages presented in the program, three stood out. The first is that bridging the scientific gap to bring the promising lead in the lab to a therapy or treatment for the patient is a long, complicated process not readily understood by the public. The second is that research organizations and drug companies need to temper the hype surrounding the excitement of a new discovery with the reality of the hard road ahead to testing and approval of a drug or treatment.

In the days surrounding most large research conferences, such as the recent American Association of Cancer Research’s annual meeting in Chicago, my inbox fills with press releases from pharma and biotech companies, universities, and research institutes, describing—in hopeful terms—the latest research advance, discovery, or progress. While a few press releases describe advances that are truly novel, most offer little information, insight, or real news about drug research developments.

I understand the challenges of a lengthy research process and the need to secure funding to continue the efforts. However, the accompanying public relations efforts need to keep in mind the ultimate goal—developing an effective drug to treat patients.

The third, and most concerning issue addressed in the NOVA program, was the legal, moral, and ethical dilemmas that the availability of personal DNA information brings. Would you want to know if you are predisposed to a certain disease? Will that information help you plan your life? Will it hurt your chances at getting a job if an insurance company tells your potential employer? Will you select a spouse based on their genetic makeup?

These questions make many people uneasy. The pitches of commercial testing labs, as profiled in the program, are also unnerving and according to some experts, unproven and potentially misleading to the public. Call me old-fashioned, but I’m not ready to order a potentially life-changing medical test (without a physician’s direction or advice) over the Internet as I would order a book, sweater, or lamp. I think I will wait for the hype to turn to hard science.

Related Articles Read More >

Eli Lilly facility
9 R&D developments this week: Lilly builds major R&D center, Stratolaunch tests hypersonic craft, IBM chief urges AI R&D funding
professional photo of wooly mammoth in nature --ar 2:1 --personalize sq85hce --v 6.1 Job ID: 47185eaa-b213-4624-8bee-44f9e882feaa
Why science ethicists are sounding skepticism and alarm on ‘de-extinction’
ALAFIA system speeds complex molecular simulations for University of Miami drug research
3d rendered illustration of the anatomy of a cancer cell
Funding flows to obesity, oncology and immunology: 2024 sales data show where science is paying off
rd newsletter
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest info on technologies, trends, and strategies in Research & Development.
RD 25 Power Index

R&D World Digital Issues

Fall 2024 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R&D magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • Global Funding Forecast

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • R&D World Home
  • Topics
    • Aerospace
    • Automotive
    • Biotech
    • Careers
    • Chemistry
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Software
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
    • Semiconductors
  • R&D Market Pulse
  • R&D 100
    • Call for Nominations: The 2025 R&D 100 Awards
    • R&D 100 Awards Event
    • R&D 100 Submissions
    • Winner Archive
    • Explore the 2024 R&D 100 award winners and finalists
  • Resources
    • Research Reports
    • Digital Issues
    • R&D Index
    • Subscribe
    • Video
    • Webinars
  • Global Funding Forecast
  • Top Labs
  • Advertise
  • SUBSCRIBE